KCTD15

Across TCGA pan-cancer cohorts, KCTD15 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KCTD15 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KCTD15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCTD15 expression acts as an unfavorable survival marker.

BLCA, LUAD, and UCEC are the cancer types where KCTD15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.141	0.655	.002	27	view →
LUAD	OS	Median	All	0.206	0.837	<.001	12	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
STAD	DFS	Median	II,III,IV	0.089	0.615	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KCTD15–BLCA (OS)

Open the BLCA breakdown →